Century Therapeutics (IPSC) Other Non-Current Liabilities (2024 - 2026)

Century Therapeutics (IPSC) has 3 years of Other Non-Current Liabilities data on file, last reported at $1.9 million in Q1 2026.

• Other Non-Current Liabilities for Q1 2026 came in at $1.9 million, down 77.19% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.9 million (down 77.19% YoY), and the FY2025 annual result was $3.8 million, down 57.0% from the prior year.
• Other Non-Current Liabilities retreated to $1.9 million in Q1 2026 per IPSC's latest filing, from $3.8 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $9.3 million in Q2 2024 and troughed at $20000.0 in Q1 2024.
• A 3-year average of $5.7 million and a median of $8.5 million in 2025 frame the typical range for Other Non-Current Liabilities.
• On a YoY basis, Other Non-Current Liabilities climbed as much as 42400.0% in 2025 and fell as far as 91.27% in 2025.
• A 3-year view of Other Non-Current Liabilities shows it stood at $8.7 million in 2024, then sank by 57.0% to $3.8 million in 2025, then sank by 48.39% to $1.9 million in 2026.
• Business Quant data shows IPSC's Other Non-Current Liabilities at $1.9 million in Q1 2026, $3.8 million in Q4 2025, and $784000.0 in Q3 2025.